Summit Therapeutics Inc. (SMMT) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Cambridge, MA, United States. Der aktuelle CEO ist Robert W. Duggan.
SMMT hat IPO-Datum 2015-03-05, 159 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $15.52B.
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to treat infectious diseases in the United States and Latin America. The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic currently in Phase III clinical trials for Clostridioides difficile infection (CDI). Summit's pipeline also includes SMT-738, designed to address multidrug-resistant infections such as carbapenem-resistant Enterobacteriaceae, and the DDS-04 series for treating Enterobacteriaceae infections. Founded in 2003 and headquartered in Cambridge, Massachusetts, the company is advancing its clinical programs to address critical unmet needs in infectious disease treatment.
